Picomolar Dichotomous Activity of Gnidimacrin Against HIV-1
Figure 5
Enzastaurin abrogated the anti-HIV-1 activity of gnidimacrin and prostratin.
CD8-depleted PHA activated PBMCs were treated with enzastaurin at indicated concentrations for 2 hours. The enzastaurin treated PBMCs were then infected with HIV-1 BaL in the presence of various concentrations of enzastaurin and 0.1 nM of gnidimacrin or 0.5 uM of prostratin. The culture supernatants were assayed for p24 on day 7 post infection. The virus replication (p24) in the presence of enzastaurin without gnidimacrin or prostratin is defined as 100% control. Each data point in the figure represents the mean +/− standard deviation of three independent experiments.